Antibody Response and Variant Cross-Neutralization After SARS-CoV-2 Breakthrough Infection

Breakthrough infections after vaccination against SARS-CoV-2 are increasingly reported, possibly due to waning of vaccine-induced antibody levels.1 Moreover, emerging variants of concern with diminished susceptibility to vaccine-induced antibodies are responsible for most new cases.2,3 Studies have focused on determining the rate of vaccine breakthrough based on antibody levels after standard vaccination practices.4,5 We […]

Read More

Antibody Titers Before and After a Third Dose of the SARS-CoV-2 BNT162b2 Vaccine in Adults Aged ≥60 Years

The durability of response to the SARS-CoV-2 BNT162b2 vaccine (Pfizer-BioNTech) in adults aged 60 years and older has yet to be determined. The immune response to 2 doses of BNT162b2 is lower in individuals aged 65 to 85 years vs 18 to 55 years.1 Among 4868 health care workers receiving 2 […]

Read More

COVID Antibody Treatment Sotrovimab Approved for Use

UK authorisation has been given for sotrovimab for patients with mild to moderate COVID-19 who are at risk of developing severe disease. The Medicines and Healthcare products Regulatory Agency (MHRA) said that the single monoclonal antibody drug was a safe and effective treatment for reducing the risk of hospitalisation and death. Results from a […]

Read More

Reduced Hospital Admission Seen in High-Risk COVID Patients Given Monoclonal Antibody Combo

NEW YORK (Reuters Health) – People with mild to moderate COVID-19 who were treated with casirivimab and imdevimab – two monoclonal antibodies with emergency-use authorization for COVID-19 in the U.S. – had lower hospitalization rates than untreated counterparts in a retrospective study. Dr. Raymund Razonable of Mayo Clinic, in Rochester, […]

Read More

7 Months After Infection, SARS-CoV-2 Antibody Levels Remain Stable or Even Increase

The levels of IgG antibodies against SARS-CoV-2 Spike protein remain stable, or even increase, seven months after infection, according to a follow-up study in a cohort of healthcare workers coordinated by the Barcelona Institute for Global Health (ISGlobal), an institution supported by “la Caixa” Foundation, in collaboration with the Hospital […]

Read More

FDA Okays Regeneron COVID-19 Antibody as Preventive in High-Risk Settings

The US Food and Drug Administration has expanded the emergency use authorization of Regeneron Pharmaceuticals Inc’s COVID-19 antibody cocktail, enabling its use as a preventive treatment for the illness in certain people. The company said the authorization enables the therapy to be used in people exposed to an infected individual, or […]

Read More